Novartis has reported result of Tasigna Phase III clinical trial. In the study, Tasigna (nilotinib) demonstrated greater efficacy over Glivec (imatinib) in the treatment of adult patients with
FDA has selected MasterControl from SynCardia Systems as the new quality management system for the Food and Drug Administration (FDA). MasterControl also provides the quality management system for
Rib-X Pharmaceuticals (Rib-X) has entered into a further license agreement with Yale University in the area of ribosome and antibiotic structure and function. Under the agreement, Rib-X is
BHR Pharma (BHR) has filed an Investigational New Drug (IND) application with the FDA for its proprietary BHR-100 intravenous progesterone infusion product. In September of this year, the
Tranzyme Pharma (Tranzyme ) has entered into a strategic collaboration agreement with Bristol-Myers Squibb, to discover, develop and commercialise macrocyclic compounds directed against targets of interest to Bristol-Myers
Viral Genetics has entered into an exclusive license agreement with the University of Colorado to develop cancer therapies based on the work of Karen Newell, a professor of
Cevec Pharmaceuticals (Cevec) and Inno Biologics have entered into a strategic license agreement. The license enables Inno Biologics to offer the full potential of production of their diagnostic
MeadWestvaco (MWV) has appointed Peter Durette as the new chief strategy officer and vice president of the company. In this new role, Mr. Durette is expected to oversee
IH Systems has conducted a study which demonstrated that RIVA System (Robotic Intravenous Automation), a self-contained unit for aseptic compounding from Intelligent Hospital Systems (IH Systems), is an
Allos Therapeutics (Allos) has provided updated data from its ongoing dose finding phase 1 study of Folotyn (pralatrexate injection) in patients with relapsed or refractory cutaneous T-cell lymphoma
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.